Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Bhargavi Kondragunta
Streamline AAV-Based Gene Therapies With High-Performing Off-The-Shelf Plasmids
By George Buchman and Bhargavi Kondragunta, Catalent Plasmids, which encode the genetic components necessary for viral replication, packaging, and gene expression, are essential starting materials in viral vector production. In adeno-associated virus (AAV) manufacturing, triple transfection typically uses three plasmids—Rep/Cap, pHelper, and the gene of interest (GOI)—to produce vectors for delivering therapeutic genes.
Streamline AAV-Based Gene Therapies With High-Performing Off-The-Shelf Plasmids
By George Buchman and Bhargavi Kondragunta, Catalent Plasmids, which encode the genetic components necessary for viral replication, packaging, and gene expression, are essential starting materials in viral vector production. In adeno-associated virus (AAV) manufacturing, triple transfection typically uses three plasmids—Rep/Cap, pHelper, and the gene of interest (GOI)—to produce vectors for delivering therapeutic genes.
Streamline AAV-Based Gene Therapies With High-Performing Off-The-Shelf Plasmids
By George Buchman and Bhargavi Kondragunta, Catalent Plasmids, which encode the genetic components necessary for viral replication, packaging, and gene expression, are essential starting materials in viral vector production. In adeno-associated virus (AAV) manufacturing, triple transfection typically uses three plasmids—Rep/Cap, pHelper, and the gene of interest (GOI)—to produce vectors for delivering therapeutic genes.
Streamline AAV-Based Gene Therapies With Superior Off-The-Shelf Plasmids
By George Buchman and Bhargavi Kondragunta, Catalent Biologics Emerging biopharmas (EBPs) may lack direct access to manufacturing, have limited knowledge about how to select or optimize product formulation and presentation, or struggle navigate the regulatory requirements of drug development.
Streamline AAV-Based Gene Therapies With Superior Off-The-Shelf Plasmids
By George Buchman and Bhargavi Kondragunta, Catalent Biologics Emerging biopharmas (EBPs) may lack direct access to manufacturing, have limited knowledge about how to select or optimize product formulation and presentation, or struggle navigate the regulatory requirements of drug development.
Optimization of AAV production for high-yielding and scalable GMP processes
The cell and gene therapy market continues to grow rapidly due to increases in the number of approvals for commercial use, molecules reaching late-stage clinical studies, and early-stage targets in development. With this growth, there is a need for critical raw-materials suppliers to develop strategies and products that enable this expansion.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Bhargavi
Contact Bhargavi, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack